Stocks and Investing
Stocks and Investing
Fri, March 13, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mayank Mamtani Maintained (ARWR) at Strong Buy with Decreased Target to $57 on, Mar 13th, 2020
Mayank Mamtani of B. Riley Securities, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Decreased Target from $83 to $57 on, Mar 13th, 2020.
Mayank has made no other calls on ARWR in the last 4 months.
There are 6 other peers that have a rating on ARWR. Out of the 6 peers that are also analyzing ARWR, 3 agree with Mayank's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Alethia Young of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $55 on, Thursday, February 6th, 2020
- Esther Rajavelu of "Oppenheimer" Initiated at Hold on, Friday, December 13th, 2019
- Elemer Piros of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $50 on, Tuesday, November 19th, 2019
These are the ratings of the 3 analyists that currently disagree with Mayank
- Mani Foroohar of "SVB Leerink" Initiated at Sell and Held Target at $32 on, Tuesday, January 21st, 2020
- Joel Beatty of "Baird" Upgraded from Hold to Buy and Increased Target to $70 on, Monday, November 25th, 2019
- Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $59 on, Wednesday, November 13th, 2019